As more details become available for the Administrations agreements, we will see how state Medicaid responds. The Department of Health and Human Services referred questions to the White House, which did not respond to requests for comment on states termination of Medicaid coverage for the weight loss drugs
Lingvay I, Brown-Frandsen K, Colhoun HM et al
The Findings Should Be Taken With a Grain of Salt The findings bring attention to symptoms that arent consistently reported in GLP-1 clinical trials, or symptoms that failed to meet the threshold for reporting, wrote the authors
GLP-1s on their own have a low risk of hypoglycemia
GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy), were originally developed to treat type 2 diabetes
The question is not whether this market will keep growingit will